Investigational drug · Phase 3
F520
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Cancer of Unknown Primary Site.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
9
Any phase or sponsor naming "F520"
First trial start
2026
Jul 8, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "F520", any sponsor or status.
Conditions studied
As listed on its trial records.
- Cancer of Unknown Primary Site
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "F520" as an intervention, largest first.
- A Phase II/III Study of F520 Combined With Paclitaxel Plus Carboplatin in the Treatment of Cancer of Unknown Primary (CUP)Pivotal-lookingRecruiting
Shandong New Time Pharmaceutical Co., LTDIndustry
NCT07761429 · 402 participants (planned) · Start Jul 8, 2026 · Primary completion Dec 30, 2027
Drug: F520 combined with chemotherapy; placebo combined with chemotherapy · For: Cancer of Unknown Primary Site
Sites: Shanghai, China
- Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid TumorsStatus unknown
Shandong New Time Pharmaceutical Co., LTDIndustry
NCT05740215 · 158 participants (planned) · Start May 23, 2022 · Primary completion May 22, 2024
Drug: F520; Lenvatinib · For: Solid Tumors
Sites: Chongqing, China
- The Efficacy and Safety of F520 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma (PTCL).Status unknown
Shandong New Time Pharmaceutical Co., LTDIndustry
NCT04457830 · 105 participants (planned) · Start Nov 1, 2020 · Primary completion Jul 31, 2022
Drug: F520 · For: Peripheral T Cell Lymphoma
Shandong New Time Pharmaceutical Co., LTDIndustry
NCT05741021 · 84 participants (planned) · Start Mar 1, 2023 · Primary completion Oct 25, 2024
Drug: F520; Pemetrexed and 2 more · For: Non-small Cell Lung Cancer; NSCLC; PD-1
Sites: Beijing, China
Shandong New Time Pharmaceutical Co., LTDIndustry
NCT04636515 · 80 participants (planned) · Start Jan 2021 · Primary completion Mar 2022
Drug: F520 · For: Locally Advanced or Metastatic Urothelial Cell Carcinoma
Shandong New Time Pharmaceutical Co., LTDIndustry
NCT03657381 · 75 participants (planned) · Start Mar 1, 2019 · Primary completion Feb 8, 2021
Drug: Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection · For: Advanced Solid Tumor,Recurrent Solid Tumor,Lymphoma,Recurrent Lymphocyte Depleted Classical Hodgkin Lymphoma
Sites: Linyi, China
- A Phase II Study to Evaluate the Efficacy and Safety of F520 Combined With F007 in Patients With RR DLBCLStatus unknown
Shandong New Time Pharmaceutical Co., LTDIndustry
NCT05178836 · 62 participants (planned) · Start Jan 1, 2022 · Primary completion Dec 31, 2023
Drug: F520+F007 · For: RR DLBCL; PD-1; CD20
Shandong New Time Pharmaceutical Co., LTDIndustry
NCT04457869 · 43 participants (planned) · Start Nov 1, 2020 · Primary completion Jul 31, 2022
Drug: F520 · For: Primary Central Nervous System Lymphoma; Secondary Central Nervous System Lymphoma
Shandong New Time Pharmaceutical Co., LTDIndustry
NCT06226350 · 29 participants · Start Mar 4, 2021 · Primary completion Dec 5, 2023
Drug: Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection · For: Cervical Cancer
Sites: Shandong, China
Newest research
PubMed records naming it or its code names, newest first.
- A programmable aptamer-triggered B-PER/CRISPR cascade amplification platform for ultrasensitive detection of Staphylococcus aureus.
Jiang J, Peng Y, Ma W, et al. · Anal Methods 2026
- Sequential detection of H2S and HClO fluorescence probes and their applications in real sample detection, smartphone sensing development, and bioimaging.
Liu Z, Yan Y, Wang H, et al. · Analyst 2025
- Research on prediction model of converter temperature and carbon content based on spectral feature extraction.
Zhao B, Zhao J, Wu W, et al. · Sci Rep 2023
- Ultra-small highly fluorescent zinc-based metal organic framework nanodots for ratiometric visual sensing of tetracycline based on aggregation induced emission.
Mohammed Ameen SS, Sher Mohammed NM, Omer KM · Talanta 2023
- A mitochondria-targeted ratiometric fluorescent nanoprobe for imaging of peroxynitrite in living cells.
Yang K, Hou L, Li Z, et al. · Talanta 2021
- Ratiometric Fluorescent Nanoprobe for Highly Sensitive Determination of Mercury Ions.
Luo Z, Xu H, Ning B, et al. · Molecules 2019
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.